Unless terminated earlier pursuant to this ARTICLE 10, the term of this Agreement shall commence on the Effective Date and shall continue in full force and effect until (i) the end of the R&D Term, if Allergan is not Developing at least one Licensed Compound or Licensed Product as of such date or, (ii) if Allergan is Developing at least one (1) Licensed Compound or Licensed Product as of the end of the R&D Term, then, as determined on a Licensed Product-by-Licensed Product and country-by-country basis, until the expiration of the Royalty Term for such Licensed Product in such country (the “ Term ”). Upon expiration of the Royalty Term, on a Licensed Product-by-Licensed Product, Permitted Indication-by-Permitted Indication and country-by-country basis, the license granted to Allergan pursuant to Section 2.1 shall become worldwide, fully paid, irrevocable and perpetual. Notwithstanding anything herein to the contrary, Sections 10.1, 10.7, 10.9, 10.10, 10.11, 10.12 and ARTICLE 13 shall become effective on the Execution Date.